A game-changer for obesity and heart failure? Dr Pandey reveals breakthrough GLP-1 trial results that show reduced cardiovascular risk and better outcomes for HFpEF patients. Don’t miss this!
Liraglutide, a GLP-1 significantly lowers the rate of recurrent stroke in patients with diabetes, with no apparent increase ...
HealthDay News — For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions, including ...
Share on Pinterest A new study compares the risks and benefits of using GLP-1 medications. Iuliia Burmistrova/Getty Images The use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback